Content area
Full text
The American Thrombosis and Hemostasis Network (ATHN) has announced that Novo Nordisk will provide start-up funding through a significant unrestricted grant over the course of five years to help establish and grow the organizational leadership and operational infrastructure of the network. Founded in July 2006, ATHN provides stewardship of a secure national database, which will be used to support clinical outcomes analysis, research, advocacy and public health reporting in the thrombosis and hemostasis community.
"Novo Nordisk has a steadfast dedication to social responsibility and we are honored by this investment in ATHN's future," said Diane Aschman, president and CEO of ATHN. "This unrestricted grant will allow us to truly begin defining and standardizing a secure, national database, and the processes surrounding...